STAY INFORMED. VISIT NHIA.ORG/COVID19 FOR INFORMATION AND RESOURCES ABOUT CORONAVIRUS DISEASE (COVID-19).

Advocacy News

NHIA to HHS: Make Medicare Payment for COVID-19 mABs Permanent

May 24, 2022

NHIA sent a letter to HHS requesting that the agency make permanent Medicare payment for COVID-19 monoclonal antibodies (mABs). HHS’s vaccine program created coverage for home and suite-based infusions of COVID mABs, which is set to expire at the end of the year in which the public health emergency (PHE) is terminated. NHIA points out that access to home infusion for mABs for the treatment and prevention of hospitalization and death due to severe COVID-19 and is critical to maintaining preparedness for potential future variants. With no oral therapies approved for prophylaxis, mABs are the only source of preventive therapy for vulnerable patients who do not respond to vaccines, such as transplant patients, cancer patients, and the immunocompromised.

Related Posts

NHIA Releases Comments on California Senate Bill 958

NHIA submitted comments on California SB 958, the Medication and Patient Safety Act of 2022, supporting amendments to the proposed legislation that allow for infused medications to be administered in the enrollee’s home when the physician and patient determine it is in the patient’s best interest and weighing in on various other aspects of the bill.

Read More »

National Home Infusion Foundation Launches Infusion Journal

The National Home Infusion Foundation (NHIF) is proud to announce the publication of the first issue of Infusion Journal. The new scholarly journal features independent research and studies related to infused therapies, patient outcomes, medication safety, economic analyses, and case studies.

Read More »